Urea for Treatment of SIAD Induced Hyponatremia: Experience of an Oncology Center
Clinical Endocrinology · 2026
DOI: 10.1111/cen.70044 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Sara Gil Dos Santos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal. Hauptthemen laut MEDLINE: Hyponatremia, Inappropriate ADH Syndrome, Urea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Introduction
Inappropriate antidiuresis syndrome (SIAD) induced hyponatremia is the most common electrolyte disturbance found in cancer patients. Available treatment options are limited by their poor efficacy, tolerability, or cost. Urea is a promising alternative, but its use in the oncology setting remains insufficiently characterized. We aimed to evaluate the efficacy and safety of urea in the management of chronic SIAD‐induced hyponatremia in patients with cancer.
Methods
We conducted a retrospective observational study of patients diagnosed with SIAD and treated with oral urea at our Oncology Center between August 2021 and June 2023. Sodium levels were recorded before urea initiation, at the first reevaluation and at the last available follow‐up.
Results
The cohort included 28 patients, mostly men (71%), with a mean age of 63.9 ± 10.0 years; 86% had metastatic disease. Lung cancer was the most frequent diagnosis, mostly small cell lung carcinoma. Urea treatment resulted in a statistically significant increase in serum sodium both in inpatients (mean increase of 2.4 ± 3.5 mmol/L after 12 (23) hours, p = 0.016) and outpatients (mean increase of 8.6 ± 6.6 mmol/L after 8 (11) days, p = 0.003). No cases of sodium overcorrection or clinically significant adverse events were reported. One patient complained of urea taste, with no impact on treatment adherence. Sodium normalization following cancer treatment allowed for urea discontinuation in 21% of cases. Median follow‐up was 84 days (range 3 days–20.9 months).
Conclusion
Our study suggests that urea may be a safe, effective, and well‐tolerated option for the long‐term management of SIAD‐related hyponatremia in oncology patients, but further studies are necessary to confirm these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal.
ORCID-Profile: Sara Gil Dos Santos
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Gil Dos Santos, S., Calheiros, R., Oliveira, J., Inácio, I., Santos, A. P., & Souteiro, P. (2026). Urea for Treatment of SIAD Induced Hyponatremia: Experience of an Oncology Center. Clinical Endocrinology. https://doi.org/10.1111/cen.70044
Vancouver
Gil Dos Santos S, Calheiros R, Oliveira J, Inácio I, Santos AP, Souteiro P. Urea for Treatment of SIAD Induced Hyponatremia: Experience of an Oncology Center. Clinical Endocrinology. 2026. doi:10.1111/cen.70044
BibTeX
@article{GilDosSantos2026,
author = {Gil Dos Santos, Sara and Calheiros, Raquel and Oliveira, Joana and Inácio, Isabel and Santos, Ana Paula and Souteiro, Pedro},
title = {Urea for Treatment of SIAD Induced Hyponatremia: Experience of an Oncology Center},
journal = {Clinical Endocrinology},
year = {2026},
doi = {10.1111/cen.70044}
}
EUVIMED